ReviewFrontiers in endocrinology2019
Emerging Trend in the Pharmacotherapy of Osteoarthritis.
Review in Frontiers in endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 3 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- Colchicine combination therapy increases treatment tolerance in patients with arthritis: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Knowledge mapping of autophagy in osteoarthritis from 2004 to 2022: A bibliometric analysis.Frontiers in immunology · 2023Pooled it
- The Efficacy of Nerve Growth Factor Antibody for the Treatment of Osteoarthritis Pain and Chronic Low-Back Pain: A Meta-Analysis.Frontiers in pharmacology · 2020Pooled it
- The effect of self-administered acupressure on pain severity and sleep quality of patients with knee osteoarthritis: a randomized controlled trial.BMC complementary medicine and therapies · 2024Trial
- TLC599 in patients with osteoarthritis of the knee: a phase IIa, randomized, placebo-controlled, dose-finding study.Arthritis research & therapy · 2022Trial
- Article
- Article
- Advancement on localized targeting via intra-articular administration of lipid-based vesicular nanoparticles for osteoarthritis management.Journal of nanobiotechnology · 2026Review
- Circular RNA circPLXNC1 functions as an inhibitor of senescence by regulating autophagy in osteoarthritis.International journal of biological sciences · 2026Article
- Metabolomics and Network Pharmacology Analyses Reveal the Mechanism of Moxibustion in Knee Osteoarthritis.Combinatorial chemistry & high throughput screening · 2026Article
- Effects of nocturnal melatonin-based tissue-bone homeostasis manipulation at varying time points on pain and central mechanisms in individuals with knee osteoarthritis: a randomized controlled trial.Frontiers in bioengineering and biotechnology · 2026Article
- Production of a risk mitigation matrix and four-grade threshold scale using Cox Regression to predict osteoarthritis development.Open life sciences · 2026Article
- Integrating bioinformatics, molecular dynamics simulation and experimental verification to screen diagnostic biomarkers for polyamine metabolism-related osteoarthritis and predict potential drugs.Journal of orthopaedic surgery and research · 2025Article
- Intraarticular resiniferatoxin, a potent TRPV1 agonist, for treatment of osteoarthritic pain.Pain management · 2025Review
- Article
- A preliminary bioinformatic screen to identify SRI SMC2 PSIP1 TLE4 and MSX1 as potential diagnostic and prognostic markers of osteoarthritis.Scientific reports · 2025Article
- Pharmacist-Driven Chondroprotection in Osteoarthritis: A Multifaceted Approach Using Patient Education, Information Visualization, and Lifestyle Integration.Pharmacy (Basel, Switzerland) · 2025Review
- Network toxicology and immune-metabolic dysregulation: linking per- and polyfluoroalkyl substances exposure to osteoarthritis pathogenesis.Toxicology research · 2025Article
- RMRP variants inhibit the cell cycle checkpoints pathway in cartilage‑hair hypoplasia.Molecular medicine reports · 2025Article
- Antidepressants to Manage Osteoarthritic Pain: The Value of Pain Phenotyping.Drugs & aging · 2025Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a degenerative joint disorder and one of the most prevalent diseases among the elderly population. Due to the limited spontaneous healing capacity of articular cartilage, it still remains challenging to find satisfactory treatment for OA. This review covers the emerging trends of pharmacologic therapies for OA such as traditional OA drugs (acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, serotonin-norepinephrine reuptake inhibitors (SNRIs), intra-articular injections of corticosteroids, and dietary supplements), which are effective in pain relief but not in reversing damage, and are frequently associated with adverse events. Alternatively, disease-modifying drugs provide promising alternatives for the management of OA. The development of these emerging OA therapeutic agents requires a comprehensive understanding of the pathophysiology of OA progression. The process of cartilage anabolism/catabolism, subchondral bone remodeling and synovial inflammation are identified as potential targets. These emerging OA drugs such as bone morphogenetic protein-7 (BMP-7), fibroblast growth factor-18 (FGF-18), human serum albumin (HSA), interleukin-1 (IL-1) inhibitor, β-Nerve growth factor (β-NGF) antibody, matrix extracellular phosphoglycoprotein (MEPE) and inverse agonist of retinoic acid-related orphan receptor alpha (RORα) etc. have shown potential to modify progression of OA with minimal adverse effects. However, large-scale randomized controlled trials (RCTs) are needed to investigate the safety and efficacy before translation from bench to bedside.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.